NCT07226076 Methadone in TKA for Post-op Pain and Opioid Reduction
| NCT ID | NCT07226076 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Medical University of South Carolina |
| Condition | Post Operative Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 162 participants |
| Start Date | 2026-01-08 |
| Primary Completion | 2026-12-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 162 participants in total. It began in 2026-01-08 with a primary completion date of 2026-12-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized, double-blind controlled trial investigates whether intraoperative IV methadone (0.15 mg/kg based on ideal body weight) reduces acute postoperative pain and opioid consumption in patients undergoing elective total knee arthroplasty under spinal anesthesia with mepivacaine.
Eligibility Criteria
Inclusion * Ages 18-75 years of age * Undergoing elective primary total knee arthroplasty with mepivacaine in the spinal anesthesia Exclusion * Allergy to methadone or mepivacaine * Severe liver disease defined as Child's Pugh Class C * End stage renal disease requiring dialysis * Known diagnosis of prolonged QT syndrome * Currently pregnant * Unable to provide written, informed consent * Non-English speaking
Contact & Investigator
William Barrett, M.D.
PRINCIPAL INVESTIGATOR
Medical University of South Carolina
Frequently Asked Questions
Who can join the NCT07226076 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Post Operative Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07226076 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 162 participants.
Is NCT07226076 currently recruiting?
Yes, NCT07226076 is actively recruiting participants. Contact the research team at nitchie@musc.edu for enrollment information.
Where is the NCT07226076 trial being conducted?
This trial is being conducted at Charleston, United States.
Who is sponsoring the NCT07226076 clinical trial?
NCT07226076 is sponsored by Medical University of South Carolina. The principal investigator is William Barrett, M.D. at Medical University of South Carolina. The trial plans to enroll 162 participants.